1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Year-End Spending Bill Sets FDA 2023 Budget At $6.6B

 
• By Elizabeth Orr

In addition to higher spending, the omnibus package now before the US Congress also addresses dual submissions, cybersecurity, pandemic preparedness, and more.  

US FDA with cloud dollars. photo illustration with Alamy and Shutterstock images
• Source: photo illustration/Alamy, Shutterstock images

The US Food and Drug Administration will see a major funding boost in the year-end omnibus spending bill, expected to pass Congress this week, with lawmakers allotting $6.6bn for the agency – up $226m from the 2022 budget. That includes $736.4m for the Center for Devices and Radiological Health.

The package doesn’t include much-anticipated diagnostics reform, which would have allowed the device center greater regulatory authority over lab-developed tests. But other FDA-related provisions in the package are drawing...

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.